Retrospective study on characteristics and outcomes in hospitalised patients treated with Ondexxya

Study identifier:D9603R00007

ClinicalTrials.gov identifier:NCT05898412

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Retrospective real world evidence study to describe characteristics and outcomes in Dutch patients admitted to the hospital with a factor Xa inhibitor-associated bleeding treated with andexanet alfa

Medical condition

Hemorrhage

Phase

N/A

Healthy volunteers

No

Study drug

Andexanet alfa

Sex

All

Estimated Enrollment

100

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 06 Oct 2023
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

LOGEX Healthcare Analytics Amsterdam The Netherlands

Inclusion and exclusion criteria